Melanoma Research Victoria

Source: OnClive, December 2018 The addition of a novel PD-1 inhibitor to a combination of BRAF inhibitor dabrafenib (Tafinlar) and MEK inhibitor trametinib (Mekinist) is being tested to determine whether the triplet is safe and effective for patients with metastatic or unresectable melanoma. Although the combination of BRAF and MEK inhibitors is already a preferred […]

Read the full story

Source: Immuno-Oncology News, December  2018 A combination of Tavo (tavokinogene telseplasmid/IL-12) and Keytruda(pembrolizumab) was effective at reducing tumors in advanced melanoma patients who had failed prior anti-PD-1 therapies, according to early results of a Phase 2b trial. OncoSec Medical’s Tavo is intended to deliver the immune-stimulating protein interleukin-12 (IL-12) into the tumor microenvironment, inducing controlled and localized production of […]

Read the full story

Source: Medical Express, December 2018 A class of cancer drugs called protein kinase inhibitors is one of the most effective treatments for melanoma. However, in many cases, tumors eventually become resistant to the drugs and cause a relapse in the patient. A new study from MIT suggests that combining kinase inhibitors with experimental drugs known […]

Read the full story

Source: Immuno-Oncology News, December 2018 A combination of Yervoy (ipilimumab) and Idera Pharmaceuticals’ investigational tilsotolimod reduced tumors in four out of 10 advanced melanoma patients included in a Phase 1/2 trial. Findings from the ILLUMINATE-204 trial (NCT02644967) were presented at the European Society for Medical Oncology (ESMO) 2018 Congress, Oct. 19-23 in Munich, Germany. The poster was titled “Intratumoral (IT) Injection of the TLR9 […]

Read the full story